Problems sleeping with prostate cancer: exploring possible risk factors for sleep disturbance in a population-based sample of survivors

AbstractPurposeThis  study aimed to investigate the prevalence of sleeping problems in prostate cancer survivors and to explore the role of predisposing, precipitating and perpetuating factors in this process.MethodsUsing a cross-sectional design, 3348 prostate cancer survivors between 2 and 18  years post diagnosis reported experiences of insomnia using the QLQC30, along with their sociodemographic characteristics, health status and treatment(s) received. The EQ5D-5L and QLQPR25 assessed survivors’ overall and prostate cancer–specific health-related quality of life. A hierarchical mu ltiple regression analysis was constructed with three blocks: (1) predisposing (e.g. demographics at diagnosis), (2) precipitating (e.g. disease extent, treatment) and (3) perpetuating factors (e.g. side effects).ResultsNineteen percent of survivors reported significant problems sleeping. The final model accounted for 31% of the variance in insomnia scores (p 
Source: Supportive Care in Cancer - Category: Cancer & Oncology Source Type: research

Related Links:

AbstractBackgroundPrevious studies have identified that patients withEGFR mutations tend to have better responses to targeted therapy, as well as chemotherapy; however, the effect of genetic alterations in terms of radiotherapy (RT) ‐related outcomes has not been fully assessed. We studied the impact of common non‐small cell lung cancer (NSCLC) genetic alterations (EGFR,ALK andKRAS) in relation to objective response rate (ORR) to RT in patients with brain metastases.MethodsFrom 2009 –2015, 153 patients with an available genotyping status were treated with whole‐brain irradiation (WBI) before receiving systemic ...
Source: Thoracic Cancer - Category: Cancer & Oncology Authors: Tags: ORIGINAL ARTICLE Source Type: research
ConclusionsEndostar delivered by CIV with CCRT may be a better option than IV in terms of potential survival and safety for unresectable stage III NSCLC.Key pointsSignificant findings of the study Endostar delivered by continuous intravenous pumping might achieve more favorable survival over intravenous injection and reduce adverse hematological reactions in patients with unresectable stage III NSCLC treated with Endostar combined with CCRT.What this study adds The administration route of recombinant human endostatin is also one key factor for survival and safety to consider when treating patients with unresectable stage III NSCLC.
Source: Thoracic Cancer - Category: Cancer & Oncology Authors: Tags: ORIGINAL ARTICLE Source Type: research
ConclusionsThe use of osimertinib immediately after nivolumab significantly increased the frequency of grade 3 or higher hepatotoxicity in patients with advanced NSCLC harboringEGFR mutation acquired T790M resistance.
Source: Thoracic Cancer - Category: Cancer & Oncology Authors: Tags: ORIGINAL ARTICLE Source Type: research
Authors: Dietrich DE, Bode L, Spannhuth CW, Hecker H, Ludwig H, Emrich HM Abstract BACKGROUND: Whether Borna disease virus (BDV-1) is a human pathogen remained controversial until recent encephalitis cases showed BDV-1 infection could even be deadly. This called to mind previous evidence for an infectious contribution of BDV-1 to mental disorders. Pilot open trials suggested that BDV-1 infected depressed patients benefitted from antiviral therapy with a licensed drug (amantadine) which also tested sensitive in vitro. Here, we designed a double-blind placebo-controlled randomized clinical trial (RCT) which cross-lin...
Source: BMC Pharmacology and Toxicology - Category: Drugs & Pharmacology Tags: BMC Pharmacol Toxicol Source Type: research
To gain a better understanding of the factors that govern in vivo cellular recognition, artificial glycoproteins are created as biomimetic probes to study the influence of specific glycan assemblies to biodistribution. The principle aim of this Review is to present pioneering research that has driven artificial glycoprotein ‐based targeting and subsequent adaptations with potential therapeutic applications. AbstractAkin to a cellular “fingerprint,” the glycocalyx is a glycan‐enriched cellular coating that plays a crucial role in mediating cell‐to‐cell interactions. To gain a better understanding of the ...
Source: Small - Category: Nanotechnology Authors: Tags: Review Source Type: research
This correction reports and rectifies errors in several articles published in JAACAP between 2009 and 2011. Incorrect coding of the Suicidal Ideation Questionnaire-Jr resulted in the wrong reporting of the means for this measure and of the rate of participants with clinically significant suicidal ideation. The authors would like to apologize to the editorial staff and the readers for these mistakes.
Source: Journal of the American Academy of Child and Adolescent Psychiatry - Category: Psychiatry Tags: Correction Source Type: research
L-GILZ binds and inhibits nuclear factor κB nuclear translocation in undifferentiated thyroid cancer cells. J Chemother. 2020 Feb 18;:1-5 Authors: Marchetti MC, Cannarile L, Ronchetti S, Delfino DV, Riccardi C, Ayroldi E Abstract Proto-oncogene mutations and abnormal activation of mitogen-activated protein kinase (MAPK) signalling are recurrently found in thyroid cancers. Some thyroid neoplasms respond to drugs that inhibit MAPK pathway activation. Previously, we showed that pharmacological inhibition of MAPK in thyroid cancer cells inhibits cell proliferation and upregulates L-GILZ (long glucoco...
Source: Journal of Chemotherapy - Category: Cancer & Oncology Tags: J Chemother Source Type: research
Authors: Maruta M, Miyoshi T, Matsuo N, Yamashina T, Irie K, Tsuruta M, Tsukada H, Tsuruyama M, Nagano M, Hiraki Y Abstract We administered FOLFOX (oxaliplatin (L-OHP) plus infusional 5-fluorouracil (5-FU) and leucovorin) to an hemodialysis (HD) patient with advanced gastric cancer (AGC), and investigated pharmacokinetics (PKs) and dialyzability of L-OHP. The patient was a 54-year-old Japanese man with a diagnosis of inoperable AGC. FOLFOX was instituted 3 h prior to the start of a 4 h HD period with the L-OHP and 5-FU doses reduced by 50% for the first cycle, and 30% reduced dose was administered for...
Source: Journal of Chemotherapy - Category: Cancer & Oncology Tags: J Chemother Source Type: research
CONCLUSIONS: Despite the retrospective nature of the observations and the low number of enrolled patients, the application of MRgRT in LACC appears to be safe and feasible with a favorable toxicity profile and response rates comparable to gold standard, supporting the setup of larger prospective studies to investigate the potentialities of this new technology. PMID: 32066345 [PubMed - as supplied by publisher]
Source: Tumori - Category: Cancer & Oncology Tags: Tumori Source Type: research
00:00 to 02.26—Dr. Bihari gives his background and credentials. Dr. Bihari: My medical training started at Harvard Medical School. I graduated in 1957. Then I trained in Internal Medicine at one of the Harvard teaching hospitals in Boston, Beth Israel, and then in Neurology at Massachusetts General in Boston. Then I went to the National Institutes of Health for two years doing brain physiology—brain research. I did another residency training in Psychiatry in New York, at Columbia Presbyterian Medical Center and then, over the following five or six years, I got very involved in working in Drug Addiction. By 197...
Source: HONEST MEDICINE: My Dream for the Future - Category: Consumer Health News Authors: Tags: Anecdotal Treatments HONEST MEDICINE Integrative Medicine Low Dose Naltrexone Obituaries Source Type: blogs
More News: Anxiety | Cancer | Cancer & Oncology | Depression | Education | Health Management | Hormones | Insomnia | Pain | Prostate Cancer | Sleep Disorders | Sleep Medicine | Study | Universities & Medical Training